Quanterix Corporation (QTRX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The ...

Quanterix (QTRX) FY Conference Summary Company Overview - Quanterix operates in the life sciences tools and diagnostics industry, focusing on ultra-sensitive protein measurement platforms based on digital ELISA [2][4] Key Points and Arguments Financial Guidance and Performance - The company anticipates a significant decline in its core Calynterex business for 2025 [2] - Despite macroeconomic pressures, the consumables business generated approximately $100 million, showing resilience compared to the previous year [4] - Diagnostics revenues tripled, indicating growth potential despite being a small segment [5] - Academic revenues were expected to decline by 20% to 30%, with an actual decline of 18% [6] - The Accelerator business saw a year-over-year revenue drop of 60%, with $4 million in revenue for the quarter [9][10] Business Segments - The Accelerator business had strong performance in previous years but is currently facing pressure due to smaller project sizes and budget constraints [11][12] - The Akoya business is projected to generate $30 million in the second half of the year, down from $82 million last year, primarily due to CDx business milestones [15] Strategic Initiatives - Quanterix aims to create a unified company structure post-Akoya acquisition, focusing on assay development and expanding consumables [19][24] - The company is targeting $85 million in annualized synergies by the end of next year, with 75% already implemented [23] - R&D investment is projected to be 30% of total revenues, emphasizing the importance of innovation [24] Product Development and Market Trends - The upcoming launch of the SMO-one platform aims to enhance sensitivity and multiplexing capabilities for liquid biopsy testing in neurology and oncology [28][29] - The Lucent AD Complete test is positioned as a significant advancement in Alzheimer's diagnostics, with plans for FDA submission and reimbursement efforts [34][36] - The company is actively working on integrating new biomarkers into its tests, enhancing diagnostic capabilities [39] Market Position and Future Outlook - Quanterix is optimistic about the translational market, particularly in understanding spatially resolved biomarkers in tissue [21] - The company believes that the integration of Akoya will enhance its oncology capabilities and expand its customer base [44] - The goal for 2026 includes achieving cash flow breakeven and maintaining a strong balance sheet with over $100 million [52] Additional Important Insights - The company is focused on increasing throughput and efficiency in its operations, leveraging existing technologies without requiring new instruments [50] - Quanterix is committed to developing a diverse range of assays to meet market demands and drive revenue growth [47] - The management expresses confidence in achieving its strategic goals and delivering value to shareholders despite current market challenges [52][53]

Core Viewpoint - Quanterix Corporation (QTRX) has experienced a significant decline of 24.3% in its stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with a reading below 30 typically indicating this condition [2]. - QTRX's current RSI reading is 28.07, indicating that the heavy selling pressure may be exhausting itself, which could lead to a reversal in the stock's trend [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts regarding an increase in earnings estimates for QTRX, with the consensus EPS estimate rising by 23.3% over the last 30 days [7]. - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term, supporting the case for a potential turnaround [7]. Group 3: Analyst Ratings - QTRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

分组1 - Quanterix Corporation reported a quarterly loss of $0.47 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.41, and compared to a loss of $0.25 per share a year ago, indicating an earnings surprise of -14.63% [1] - The company posted revenues of $24.48 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 12.62%, and down from $34.38 million in the same quarter last year [2] - Quanterix shares have declined approximately 47.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.57 on revenues of $41.97 million, and for the current fiscal year, it is -$1.87 on revenues of $146.48 million [7] - The Zacks Industry Rank for Medical - Products is in the bottom 37% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $24.5 million, down 29% year over year due to temporary funding pauses and uncertainty in the U.S. academic and pharmaceutical end markets [15][16] - Gross profit was $11.3 million with a gross margin of 46.2%, while non-GAAP gross profit was $10.2 million with a non-GAAP gross margin of 41.8% [17][18] - Operating expenses increased to $48.4 million, up $15.2 million year over year, including significant costs related to acquisition and restructuring [19] - Adjusted EBITDA was a loss of $13.7 million compared to a loss of $4.1 million in the same quarter of the previous year [19] Business Line Data and Key Metrics Changes - Consumable revenue was $14.9 million, while instrument revenue was $2 million, with 10 instruments placed in the quarter compared to 22 in the previous year [16] - Accelerator lab revenue was $4 million, down 60%, driven by a decline in large multimillion-dollar projects from pharmaceutical customers [16] - Sales to diagnostics partners totaled $2.6 million, up from $0.7 million in the prior year period [16] Market Data and Key Metrics Changes - The customer mix was evenly split between pharma and academia, with academic sales declining 18% and pharma sales declining 38% [16] - The combined company expects to report $130 million to $135 million of revenue for 2025, with Simoa revenue expected to be $100 million to $105 million [21][22] Company Strategy and Development Direction - The company completed the transformative Equaya acquisition and is focused on sustainable double-digit revenue growth and margin improvement [6][7] - The strategic priorities include expanding the addressable market, accelerating the Simoa platform rollout, and building a foundation for an Alzheimer's diagnostic franchise [10][11][13] - The company aims to achieve approximately $85 million in synergy savings and cost reductions by 2026, with 75% of these expense reductions already implemented [7][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged temporary headwinds in academic funding and biopharma spending but expressed confidence in the long-term growth potential of proteomics [6][9] - The company is committed to achieving cash flow breakeven in 2026, even amidst challenging market conditions, and has already exceeded synergy expectations [24][25] Other Important Information - The company ended the quarter with $263.8 million in cash and equivalents, with adjusted cash usage improving by 49% year over year [20] - Akoya generated $18.2 million in Q2, contributing to the combined company's revenue outlook [21] Q&A Session Summary Question: Insights on Accelerator business and clinical trials - The Accelerator business grew approximately 40% year on year, with a net increase in customers, although project sizes are smaller than last year [29][30] Question: Academic funding outlook and customer confidence - There is strong resiliency in the consumables franchise, with approximately $100 million in consumables revenue, indicating potential positivity in academic funding [31][32] Question: Cost actions and long-term growth - The integration has focused on operating as one company, realizing significant synergies in operations and maintaining a focus on customer service while addressing cost structures [35][36]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________ FORM 10-Q _________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38319 __ ...

[Q2 2025 Earnings Overview](index=1&type=section&id=Q2%202025%20Earnings%20Overview) [CEO's Strategic Commentary](index=1&type=section&id=CEO's%20Strategic%20Commentary) Quanterix CEO Masoud Toloue highlighted the creation of a high-margin, high-throughput business through the Akoya Biosciences merger, achieving profitable growth, completing 75% of $85 million synergy targets, and expecting cash flow breakeven in 2026 - The company created a high-margin, high-throughput business with significant opportunities for profitable growth in an expanding market through the merger with Akoya Biosciences[3](index=3&type=chunk) - Pro forma consumables revenue was approximately **$100 million**[3](index=3&type=chunk) - Alzheimer's disease diagnostics revenue more than **doubled year-over-year**[3](index=3&type=chunk) - **75% of the $85 million** synergy and cost reduction targets have been achieved[3](index=3&type=chunk) - Cash flow breakeven is anticipated in **2026**[3](index=3&type=chunk) [Second Quarter Financial Highlights](index=1&type=section&id=Second%20Quarter%20Financial%20Highlights) Quanterix reported significant declines in revenue and gross margin for Q2 2025, leading to a substantial increase in net loss, primarily due to market weakness and acquisition-related impacts Key Financial Data for Q2 2025 | Metric | Q2 2025 (million USD) | Q2 2024 (million USD) | Change (%) | | :----- | :-------------------- | :-------------------- | :--------- | | Revenue | $24.5 | $34.4 | -29% | | GAAP Gross Margin | 46.2% | 64.7% | -18.5 pp | | Adjusted Gross Margin (non-GAAP) | 41.8% | 58.6% | -16.8 pp | | Net Loss | $(30.0) | $(7.4) | >300% | | Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (end of period) | $263.8 | N/A | N/A | | Adjusted Cash Usage | $(2.6) | $(5.1) | -48.9% (improvement) | [Operational and Business Highlights](index=1&type=section&id=Operational%20and%20Business%20Highlights) Key operational achievements this quarter include completing the Akoya Biosciences acquisition, launching new Alzheimer's disease detection products, and securing medical device registration approval for the pTau-217 assay kit in China - Completed the acquisition of Akoya Biosciences in early July, creating the first integrated platform capable of measuring both blood and tissue biomarkers[8](index=8&type=chunk) - Launched p-Tau 205 and p-Tau 212 assays at the Alzheimer's Association International Conference (AAIC) to advance Alzheimer's disease research[8](index=8&type=chunk) - Quanterix's UltraDx plasma pTau-217 assay kit (single molecule immunofluorescence) successfully received medical device registration approval from China's National Medical Products Administration[8](index=8&type=chunk) - Continued to build the foundation for Alzheimer's disease diagnostics through new partnerships, expanded international regulatory footprint, and increased testing volumes and revenue[8](index=8&type=chunk) [2025 Full Year Business Outlook](index=1&type=section&id=2025%20Full%20Year%20Business%20Outlook) Quanterix issued its 2025 full-year outlook, projecting reported revenue of $130-135 million (including two quarters of Akoya) and pro forma revenue of $165-170 million, with GAAP gross margin of 49-53% and approximately $120 million in cash by year-end 2025 2025 Full Year Business Outlook | Metric | 2025 Full Year Outlook | | :----- | :--------------------- | | Revenue (Reported) | $130 - $135 million | | Revenue (Pro Forma, including full year Akoya) | $165 - $170 million | | GAAP Gross Margin | 49% - 53% | | Adjusted Gross Margin (non-GAAP) | 45% - 49% | | Adjusted Cash Usage | Approximately $34 - $38 million | | Cash and Cash Equivalents (end of 2025) | Approximately $120 million | - Cash flow breakeven is anticipated in **2026**[7](index=7&type=chunk) [Company Information](index=2&type=section&id=Company%20Information) [Conference Call Details](index=2&type=section&id=Conference%20Call) Quanterix is scheduled to host a conference call on August 7, 2025, at 4:30 PM ET to discuss financial results, providing dial-in numbers and webcast options - The conference call is scheduled for **August 7, 2025, at 4:30 PM ET**[9](index=9&type=chunk) - Dial-in numbers: US and Canada toll-free (800) 715-9871 or (646) 307-1963, Conference ID: **5591565**[9](index=9&type=chunk) - Investors can listen to the webcast on the 'Events & Presentations' page of the Quanterix website's investor section, with an archived replay available for one year[9](index=9&type=chunk) [About Quanterix](index=2&type=section&id=About%20Quanterix) Quanterix is a global leader in ultrasensitive biomarker detection, leveraging its proprietary Simoa® technology and the recent Akoya Biosciences acquisition to integrate multiplex tissue imaging, creating a platform connecting blood and tissue biology to advance precision medicine - Quanterix is a global leader in ultrasensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development through its proprietary Simoa® technology[10](index=10&type=chunk) - Acquired Akoya Biosciences in **2025**, adding multiplex tissue imaging technology with single-cell resolution and **1,396 installed instruments**[10](index=10&type=chunk) - The combined company offers a unique integrated platform connecting biology between blood and tissue, advancing precision medicine from discovery to diagnostics[10](index=10&type=chunk) [Consolidated GAAP Financial Statements](index=3&type=section&id=Consolidated%20GAAP%20Financial%20Statements) [Consolidated Statements of Operations](index=3&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) In Q2 2025, Quanterix experienced significant declines in total revenue and gross profit, coupled with a substantial increase in operating expenses, resulting in a net loss of $30.0 million, a considerable expansion from $7.4 million in Q2 2024 Consolidated Statements of Operations (Unaudited, in thousand USD) | Metric | Three Months Ended June 30, 2025 (thousand USD) | Three Months Ended June 30, 2024 (thousand USD) | Six Months Ended June 30, 2025 (thousand USD) | Six Months Ended June 30, 2024 (thousand USD) | | :----------------------------- | :------------------------------------ | :------------------------------------ | :------------------------------------ | :------------------------------------ | | Total Revenue | $24,476 | $34,381 | $54,810 | $66,447 | | Gross Profit | $11,300 | $22,234 | $27,716 | $40,782 | | Total Operating Expenses | $48,400 | $33,176 | $91,183 | $66,881 | | Loss from Operations | $(37,100) | $(10,942) | $(63,467) | $(26,099) | | Net Loss | $(30,013) | $(7,387) | $(50,517) | $(18,550) | | Net Loss Per Share (Basic and Diluted) | $(0.77) | $(0.19) | $(1.30) | $(0.49) | - Product revenue decreased from **$19,887 thousand** in Q2 2024 to **$16,832 thousand** in Q2 2025[12](index=12&type=chunk) - Selling, general, and administrative expenses significantly increased from **$24,080 thousand** in Q2 2024 to **$31,353 thousand** in Q2 2025[12](index=12&type=chunk) - Impairment and restructuring charges of **$7,670 thousand** were recorded in Q2 2025, compared to none in Q2 2024[12](index=12&type=chunk) [Consolidated Balance Sheets](index=4&type=section&id=CONSOLIDATED%20BALANCE%20SHEETS) As of June 30, 2025, Quanterix's total assets decreased to $375.6 million from $406.5 million at year-end 2024, primarily due to reduced marketable securities, while total liabilities increased Consolidated Balance Sheets (Unaudited, in thousand USD) | Metric | June 30, 2025 (thousand USD) | December 31, 2024 (thousand USD) | | :----------------------------- | :----------------------------- | :--------------------------------- | | Total Assets | $375,609 | $406,533 | | Cash and Cash Equivalents | $132,896 | $56,709 | | Marketable Securities | $128,276 | $232,413 | | Total Current Assets | $322,117 | $363,594 | | Total Liabilities | $83,151 | $76,495 | | Total Stockholders' Equity | $292,458 | $330,038 | - Intangible assets, net, increased from **$4,031 thousand** to **$16,332 thousand**, likely related to the Akoya acquisition[14](index=14&type=chunk) - Accounts receivable, net, decreased from **$32,141 thousand** to **$23,549 thousand**[14](index=14&type=chunk) [Consolidated Statements of Cash Flows](index=5&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) For the six months ended June 30, 2025, Quanterix's net cash used in operating activities improved to $19.5 million from $25.1 million year-over-year, with significant cash provided by investing activities, primarily from marketable securities, leading to a net increase in cash, cash equivalents, and restricted cash Consolidated Statements of Cash Flows (Unaudited, in thousand USD) | Metric | Six Months Ended June 30, 2025 (thousand USD) | Six Months Ended June 30, 2024 (thousand USD) | | :--------------------------------------------- | :------------------------------------ | :------------------------------------ | | Net Cash Used in Operating Activities | $(19,543) | $(25,115) | | Net Cash Provided by (Used in) Investing Activities | $94,642 | $(102,220) | | Net Cash Provided by (Used in) Financing Activities | $(336) | $271 | | Net Increase (Decrease) in Cash, Cash Equivalents, and Restricted Cash | $74,763 | $(127,064) | | Cash, Cash Equivalents, and Restricted Cash at End of Period | $135,537 | $49,609 | - Purchases of marketable securities significantly decreased from **$189,344 thousand** in H1 2024 to **$30,245 thousand** in H1 2025[16](index=16&type=chunk) - Proceeds from sales and maturities of marketable securities increased from **$89,229 thousand** in H1 2024 to **$135,874 thousand** in H1 2025[16](index=16&type=chunk) - Acquisition, net of cash acquired, resulted in a cash outflow of **$8,954 thousand** in H1 2025[16](index=16&type=chunk) [Non-GAAP Financial Measures and Reconciliations](index=6&type=section&id=Non-GAAP%20Financial%20Measures%20and%20Reconciliations) [Use of Non-GAAP Financial Measures](index=6&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) Quanterix utilizes non-GAAP financial measures like Adjusted EBITDA, Adjusted Gross Profit, and Adjusted Cash Usage to provide investors with clearer insights into underlying operating performance and trends by excluding certain variable or non-recurring items - Non-GAAP financial measures are intended to provide supplemental information to help investors understand the company's underlying operating performance and trends[17](index=17&type=chunk) - Adjusted EBITDA excludes interest income, income tax (expense) benefit, depreciation and amortization expense, stock-based compensation expense, acquisition and integration-related costs, impairment and restructuring, and other highly variable, significant, and non-recurring expenses or benefits not representative of ongoing or future business operations[21](index=21&type=chunk) - Adjusted Gross Profit and operating expenses are adjusted for shipping and handling costs of product sales, amortization of certain acquired intangible assets, and acquisition and integration-related costs[21](index=21&type=chunk) - Adjusted Cash Usage excludes cash payments related to transactions or events that are highly variable, significant, and not representative of ongoing or future business operations[21](index=21&type=chunk) [Reconciliation of Net Loss to Adjusted EBITDA (non-GAAP)](index=7&type=section&id=Reconciliation%20of%20Net%20Loss%20to%20Adjusted%20EBITDA%20(non-GAAP)) Adjusted EBITDA (non-GAAP) loss for Q2 2025 was $13.7 million, significantly higher than the $4.1 million loss in Q2 2024, reflecting increased acquisition, integration, and impairment costs Reconciliation of Net Loss to Adjusted EBITDA (non-GAAP) (Unaudited, in thousand USD) | Metric | Three Months Ended June 30, 2025 (thousand USD) | Three Months Ended June 30, 2024 (thousand USD) | Six Months Ended June 30, 2025 (thousand USD) | Six Months Ended June 30, 2024 (thousand USD) | | :----------------------------- | :------------------------------------ | :------------------------------------ | :------------------------------------ | :------------------------------------ | | Net Loss | $(30,013) | $(7,387) | $(50,517) | $(18,550) | | Adjusted EBITDA (non-GAAP) | $(13,714) | $(4,122) | $(25,051) | $(12,265) | | Adjusted EBITDA Margin (non-GAAP) | (56.0)% | (12.0)% | (45.7)% | (18.5)% | - Significant adjustments in Q2 2025 included **$4,139 thousand** in acquisition and integration-related costs, **$4,156 thousand** in contingent consideration recognized as compensation expense, and **$7,670 thousand** in impairment and restructuring charges[23](index=23&type=chunk) [Reconciliation of Net Increase in Cash, Cash Equivalents, and Restricted Cash to Adjusted Cash Usage (non-GAAP)](index=7&type=section&id=Reconciliation%20of%20Net%20Increase%20in%20Cash%2C%20Cash%20Equivalents%2C%20and%20Restricted%20Cash%20to%20Adjusted%20Cash%20Usage%20(non-GAAP)) Adjusted cash usage (non-GAAP) for Q2 2025 improved to $2.6 million from $5.1 million in Q2 2024, despite a higher net cash increase, due to adjustments for acquisition, integration, and restructuring costs Reconciliation of Net Increase in Cash, Cash Equivalents, and Restricted Cash to Adjusted Cash Usage (non-GAAP) (Unaudited, in thousand USD) | Metric | Three Months Ended June 30, 2025 (thousand USD) | Three Months Ended June 30, 2024 (thousand USD) | Six Months Ended June 30, 2025 (thousand USD) | Six Months Ended June 30, 2024 (thousand USD) | | :--------------------------------------------- | :------------------------------------ | :------------------------------------ | :------------------------------------ | :------------------------------------ | | Net Increase (Decrease) in Cash, Cash Equivalents, and Restricted Cash | $55,796 | $1,696 | $74,763 | $(127,064) | | Cash Usage | $(5,703) | $(5,064) | $(27,919) | $(24,466) | | Adjusted Cash Usage (non-GAAP) | $(2,643) | $(5,064) | $(11,667) | $(24,466) | - Adjustments in Q2 2025 included **$1,987 thousand** in acquisition and integration-related cash payments and **$1,073 thousand** in restructuring costs[25](index=25&type=chunk) [Reconciliation of Gross Profit, Gross Margin, Total Operating Expenses and Loss from Operations to Non-GAAP Financial Measures](index=8&type=section&id=Reconciliation%20of%20Gross%20Profit%2C%20Gross%20Margin%2C%20Total%20Operating%20Expenses%20and%20Loss%20from%20Operations%20to%20Non-GAAP%20Financial%20Measures) Adjusted gross profit (non-GAAP) for Q2 2025 was $10.2 million, down from $20.2 million in Q2 2024, with an adjusted gross margin of 41.8%, while adjusted total operating expenses remained flat at $31.1 million year-over-year, benefiting from significant adjustments for acquisition, contingent consideration, and impairment costs Reconciliation of Gross Profit, Gross Margin, Total Operating Expenses and Loss from Operations to Non-GAAP Financial Measures (Unaudited, in thousand USD) | Metric | Three Months Ended June 30, 2025 (thousand USD) | Three Months Ended June 30, 2024 (thousand USD) | Six Months Ended June 30, 2025 (thousand USD) | Six Months Ended June 30, 2024 (thousand USD) | | :--------------------------------------------- | :------------------------------------ | :------------------------------------ | :------------------------------------ | :------------------------------------ | | Gross Profit | $11,300 | $22,234 | $27,716 | $40,782 | | Adjusted Gross Profit (non-GAAP) | $10,235 | $20,159 | $25,301 | $36,565 | | Gross Margin | 46.2% | 64.7% | 50.6% | 61.4% | | Adjusted Gross Margin (non-GAAP) | 41.8% | 58.6% | 46.2% | 55.0% | | Total Operating Expenses | $48,400 | $33,176 | $91,183 | $66,881 | | Adjusted Total Operating Expenses (non-GAAP) | $31,136 | $31,101 | $65,020 | $62,664 | | Loss from Operations | $(37,100) | $(10,942) | $(63,467) | $(26,099) | | Adjusted Loss from Operations (non-GAAP) | $(20,901) | $(10,942) | $(39,719) | $(26,099) | - Adjustments to total operating expenses in Q2 2025 included **$4,139 thousand** in acquisition and integration-related costs, **$4,156 thousand** in contingent consideration recognized as compensation expense, and **$7,670 thousand** in impairment and restructuring charges[28](index=28&type=chunk) [Additional Information](index=8&type=section&id=Additional%20Information) [CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS](index=8&type=section&id=CAUTIONARY%20STATEMENT%20REGARDING%20FORWARD-LOOKING%20STATEMENTS) This section provides a standard legal disclaimer for forward-looking statements in the press release, outlining various risks and uncertainties that could cause actual results to differ materially from projections, including those related to government policies, cost reduction benefits, product launches, acquisitions (Akoya), financial estimates, restatement risks, and market acceptance - Statements in the press release regarding Quanterix's future business outlook, operations, strategy, and financial performance are forward-looking statements[31](index=31&type=chunk) - Risks and uncertainties include the impact of US government policies, failure to realize cost reduction benefits, timing of the next-generation Simoa One instrument launch, and failure to achieve anticipated benefits and synergies from the Akoya Biosciences acquisition[32](index=32&type=chunk) - Other risks include inaccurate estimates of expenses, future revenue, capital requirements, and additional financing needs, risks related to financial statement restatements, and the ability to maintain effective internal controls[32](index=32&type=chunk) - Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of their date of publication[33](index=33&type=chunk) [Contacts](index=10&type=section&id=Contacts) Contact information is provided for media and investor relations inquiries - Media Contact: Marissa Klaassen, Phone: (978) 488-1854, Email: media@quanterix.com[34](index=34&type=chunk) - Investor Relations Contact: Joshua Young, Phone: (508) 846-3327, Email: ir@quanterix.com[34](index=34&type=chunk)

Financial Performance & Outlook - Q2 2025 revenue decreased by 29% to $24.5 million compared to $34.4 million in Q2 2024[17] - GAAP gross margin decreased to 46.2% in Q2 2025 from 64.7% in Q2 2024[17] - The company is aiming for cash flow breakeven in 2026[14] - Full year 2025 revenue guidance is $130 to $135 million, including a $30 million contribution from Spatial[21] - Adjusted cash usage for the full year 2025 is projected to be $34 to $38 million[23] Cost Reduction & Synergies - The company has implemented $64 million of the total $85 million cost reduction plan[15] - Synergy and cost actions are expected to reach $85 million[13] - $3 million cost reduction realized in Q2 2025[14] Strategic Initiatives - The company completed the acquisition of Akoya, enabling new protein biomarker measurements[10, 11] - Strategic investments are being made in new assays, the Simoa One platform, and Alzheimer's diagnostics[12] - The company is building a $100 million high-margin consumables business[13] Alzheimer's Disease Testing - Development of LucentAD multi-marker test for Alzheimer's disease with 90% sensitivity, specificity, and accuracy[16] - Anticipated submission for Single-Site IVD by the end of 2025[16] - Medicare pricing anticipated in 2025 at $897 per test proposed[16]

Core Viewpoint - Quanterix has completed the acquisition of Akoya Biosciences through a stock and cash transaction, aiming for technological complementarity and market expansion [1]. Group 1: Acquisition Details - On July 8, 2025, Quanterix announced the completion of the acquisition of Akoya Biosciences, issuing 78 million shares of common stock and paying $20 million in cash [2]. - The acquisition was structured as 1 share of Akoya stock exchanged for 0.1461 shares of Quanterix stock plus $0.38 in cash [2]. - The acquisition process began in early 2025, with initial terms proposing 1 share of Akoya stock for 0.318 shares of Quanterix stock [3]. Group 2: Strategic Objectives - The acquisition aims to combine Akoya's spatial biology with Quanterix's ultra-sensitive protein detection technology, creating technological synergies [3]. - The deal is expected to expand application areas from neurology to oncology, leveraging Akoya's partnerships to drive product entry into clinical markets [3]. - The transaction is projected to generate approximately $40 million in annual cost synergies, with $20 million expected to be realized in the first year post-transaction [3]. Group 3: Company Background - Quanterix Corporation (NASDAQ: QTRX) is a life sciences company based in Billerica, Massachusetts, founded in 2007, focusing on ultra-sensitive biomarker detection [4]. - The company's core innovation is the Simoa® (Single Molecule Array) technology, which allows for the detection of proteins and nucleic acids in blood, plasma, or serum at femtogram per milliliter sensitivity [4]. - The merger and technology integration will expand Quanterix's business from single protein detection to spatial biology, potentially enhancing its role in multi-omics research and personalized medicine [4].

Financial Data and Key Metrics Changes - The company reported record consumables revenue exceeding $18 million, reflecting strong product development efforts and an expanded assay portfolio [5][6] - The Accelerator services business grew by 36% year-on-year, although some pharma projects were pushed to later quarters due to market conditions [7][8] - Overall, the company expects to stabilize and return to a pace of clinical trials and preclinical work as the biopharma market stabilizes [8][10] Business Line Data and Key Metrics Changes - Consumables revenue showed significant growth, driven by the introduction of over 20 new assays last year and a similar cadence expected this year [5][6] - The instruments segment remained stable year-over-year, indicating consistent demand [6] - The Accelerator Lab has become a significant revenue source, contributing approximately 30% of the business and showing strong growth in clinical and market adoption [18][20] Market Data and Key Metrics Changes - The company has about 20-22% exposure to the government end market, with some paralysis in customer decisions due to uncertainties in grant funding [12][13] - The academic research market is experiencing pressure, but the company is finding ways to mitigate this through services and consumables [12][13] Company Strategy and Development Direction - The company aims to expand its addressable market from $1 billion in neurology to $5 billion by including immunology and immuno-oncology [42][43] - The introduction of the SYM-one platform is expected to enhance sensitivity and complexity in immunology and oncology, broadening the company's market reach [30][34] - The company is focused on maintaining R&D investments while implementing cost-saving measures, ensuring continued innovation in key areas [39][40] Management's Comments on Operating Environment and Future Outlook - Management noted that while there are delays in project decisions, there have been no cancellations, indicating a cautious but positive outlook for future projects [9][10] - The company is optimistic about the growth potential in the liquid biopsy market, emphasizing the importance of protein biomarkers alongside DNA [44][46] - Management believes that the adoption of blood-based biomarkers for Alzheimer's will increase as therapy adoption improves, creating a synergistic effect [54][56] Other Important Information - The company is preparing for the launch of the SYM-one platform, which will be compatible with over 20,000 flow cytometers, significantly increasing its market reach [32][36] - The company has initiated a cost savings program targeting $55 million in savings by the end of 2026, focusing on G&A and volume-related costs [38][39] Q&A Session Summary Question: Can you discuss the recent Q1 results and the impact of academic funding concerns? - The company reported strong consumables growth but noted that academic funding concerns have affected the outlook for the Accelerator Lab [4][5] Question: What is the exposure to the government end market and the impact of NIH spending cuts? - Approximately 20-22% of customers have NIH exposure, and while there is some paralysis in decision-making, the company is finding ways to support these customers [12][13] Question: How does the Accelerator Lab contribute to the business? - The Accelerator Lab has evolved into a significant revenue source, providing stability and repeat business, especially in a CapEx constrained environment [18][20] Question: What are the expectations for the SYM-one platform launch? - The SYM-one platform is expected to enhance sensitivity and complexity in immunology and oncology, with a launch planned before the end of the year [30][34] Question: How does the company plan to balance cost savings with R&D investments? - The company is implementing cost savings primarily in G&A and volume-related areas while maintaining strong investments in R&D and innovation [39][40] Question: What is the rationale behind the Akoya acquisition? - The acquisition aims to increase the addressable market and achieve synergies through a unified operating line and commercial team, targeting profitability by 2026 [42][43]